Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · February 03, 2022

Rituximab for Acetylcholine Receptor Antibody–Positive Generalized Myasthenia Gravis



Additional Info

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study
Neurology 2021 Dec 02;[EPub Ahead of Print], RJ Nowak, CS Coffey, JM Goldstein, MM Dimachkie, M Benatar, JT Kissel, GI Wolfe, TM Burns, ML Freimer, S Nations, V Granit, AG Smith, DP Richman, E Ciafaloni, MT Al-Lozi, LA Sams, D Quan, E Ubogu, B Pearson, A Sharma, JW Yankey, L Uribe, M Shy, AA Amato, R Conwit, KC O'Connor, DA Hafler, ME Cudkowicz, RJ Barohn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading